Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
PLoS One 8 (11), e78731
Addressing Metabolic Dysfunction as an Independent Cancer Risk Factor Accumulating evidence positions metabolic dysfunction characterised by insulin resistance, hepatic steatosis, dyslipidaemia, and visceral adiposity as a more powerful and proximate predictor of cancer risk than elevated body weight alone
This episode is about building that foundationwhether youre on a medication, considering one, or taking a food-first approach
Diabetes, Obesity, and Metabolism, 23 (10), 2242-2250
It is not approved specifically as a weight loss medication
US$ 29.42
US$ 22.87
US$ 24.51
